Principal Financial Group Inc. Purchases 9,128 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Principal Financial Group Inc. boosted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 291,465 shares of the medical equipment provider’s stock after buying an additional 9,128 shares during the quarter. Principal Financial Group Inc. owned approximately 0.43% of Lantheus worth $18,071,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. grew its position in shares of Lantheus by 15.1% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 7,404 shares of the medical equipment provider’s stock worth $514,000 after buying an additional 970 shares during the last quarter. NBC Securities Inc. bought a new stake in Lantheus in the third quarter valued at $46,000. Victory Capital Management Inc. boosted its holdings in Lantheus by 17.2% in the third quarter. Victory Capital Management Inc. now owns 347,595 shares of the medical equipment provider’s stock valued at $24,151,000 after acquiring an additional 51,112 shares in the last quarter. Sector Gamma AS increased its position in Lantheus by 1.3% during the 3rd quarter. Sector Gamma AS now owns 50,962 shares of the medical equipment provider’s stock valued at $3,541,000 after purchasing an additional 653 shares during the period. Finally, Wrapmanager Inc. raised its holdings in Lantheus by 14.7% in the 3rd quarter. Wrapmanager Inc. now owns 5,107 shares of the medical equipment provider’s stock worth $355,000 after purchasing an additional 653 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on LNTH shares. Truist Financial boosted their price target on shares of Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. JMP Securities restated a “market outperform” rating and issued a $100.00 target price on shares of Lantheus in a research note on Friday, February 23rd. B. Riley lifted their price target on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research report on Thursday, April 18th. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Finally, Mizuho boosted their target price on shares of Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $99.17.

Lantheus Trading Up 0.8 %

NASDAQ LNTH opened at $81.35 on Thursday. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $100.48. The company has a current ratio of 4.84, a quick ratio of 4.55 and a debt-to-equity ratio of 0.59. The stock’s fifty day moving average price is $66.43 and its 200-day moving average price is $63.86. The stock has a market cap of $5.64 billion, a P/E ratio of 12.42 and a beta of 0.52.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating the consensus estimate of $1.33 by $0.26. The company had revenue of $354.00 million for the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 5.96 EPS for the current fiscal year.

Insider Activity

In related news, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the transaction, the director now owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $76.89, for a total transaction of $26,219.49. Following the sale, the chief accounting officer now directly owns 62,898 shares in the company, valued at approximately $4,836,227.22. The disclosure for this sale can be found here. Insiders have sold a total of 94,545 shares of company stock worth $6,177,295 over the last 90 days. 2.10% of the stock is currently owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.